Develops small molecule therapeutics for neurological and respiratory diseases, focusing on novel approaches to treat diseases with unmet medical needs.
MediciNova, Inc. is a biopharmaceutical company dedicated to developing innovative small molecule therapeutics to address serious diseases with unmet medical needs in the United States. Among its key developments is MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent aimed at treating a range of neurological disorders, including primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction.
The company’s diverse product pipeline also features MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist designed for treating acute exacerbations of asthma. Additionally, MediciNova is advancing MN-001 (tipelukast), an orally bioavailable small molecule intended for treating fibrotic diseases such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. MN-029 (denibulin), a tubulin binding agent, is being developed for the treatment of solid tumor cancers.
Headquartered in La Jolla, California, MediciNova, Inc. was incorporated in 2000. The company has established collaboration agreements with several prominent pharmaceutical companies, including Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd, Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Through these partnerships and its innovative therapeutic developments, MediciNova aims to make significant advancements in the treatment of various severe medical conditions.